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Robert KlopfleischAbstract
Background: Histopathology has initially been and is still used to diagnose infectious, degenerative or neoplastic
diseases in humans or animals. In addition to qualitative diagnoses semiquantitative scoring of a lesion`s magnitude
on an ordinal scale is a commonly demanded task for histopathologists. Multiparametric, semiquantitative scoring
systems for mouse models histopathology are a common approach to handle these questions and to include
histopathologic information in biomedical research.
Results: Inclusion criteria for scoring systems were a first description of a multiparametric, semiquantiative scoring
systems which comprehensibly describe an approach to evaluate morphologic lesion. A comprehensive literature
search using these criteria identified 153 originally designed semiquantitative scoring systems for the analysis of
morphologic changes in mouse models covering almost all organs systems and a wide variety of disease models.
Of these, colitis, experimental autoimmune encephalitis, lupus nephritis and collagen induced osteoarthritis colitis
were the disease models with the largest number of different scoring systems. Closer analysis of the identified
scoring systems revealed a lack of a rationale for the selection of the scoring parameters or a correlation between
scoring parameter value and the magnitude of the clinical symptoms in most studies.
Conclusion: Although a decision for a particular scoring system is clearly dependent on the respective scientific
question this review gives an overview on currently available systems and may therefore allow for a better choice
for the respective project.
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Histopathology has initially been and is still used today
to diagnose infectious, degenerative or neoplastic dis-
eases in humans or animals. These qualitative diagnoses
are based on a sum of observable changes in the morph-
ology of the analyzed tissue. The cognition of these
changes is based on the pattern recognition of the
observer and the comparison of these patterns with
the known physiologic variation in tissue morphology
in the respective species. Decades of experience in
veterinary pathology show that this approach allows for
reproducible qualitative diagnoses by the observer but canCorrespondence: robert.klopfleisch@fu-berlin.de
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reproduction in any medium, provided the oralso be used for semiquantitative scoring of the lesions
magnitude, i.e. on an ordinal scale for instance with a low,
medium or high grade trichotomy which correlates with
the clinical relevance of the lesions.
Absolute quantification of the lesions extent and sever-
ity is however difficult since two main problems hamper
absolute quantification, i.e. on a rational scale with abso-
lute values of 1, 2, 3 etc., using standard, non-automated
histopathology. First, the detection method is not re-
liable enough. Despite intensive training and attempts
to standardize nomenclature and the definition of lesions
there are still unresolved issues in terms of interobserver
variation which may be acceptable for qualitative and semi-
quantitative evaluation but not for absolute quantitation
[1]. Second, in most circumstances it is impossible to
objectively justify the interval between two values, thus atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is impossible.
Image analysis by automated calculation of the tissue
area affected or cells present per area have been intro-
duced to overcome this problem. These approaches aim
at a reliable and reproducible histopathology read out in
a rational scale to allow proper statistical processing andTable 1 Semiquantitative scoring systems for murine intestin
Disease model Scoring syste
Colitis
DSS-induced [4] Proximal + middle + distal colon: crypt
af
DSS-induced [5] Extent, inflammation
DSS-induced [6] Crypt damage, area involved, regene
DSS-induced [7] Crypt loss (0–4), crypt distortion (0–4)
multiplied by pe
DSS-induced [8] Hyperplasia (0–3), severity
DSS-induced [9] Severity of inflammation, thickness of
epithe
DSS-induced [10] Epithelium (goblet c
DSS-induced [11] Infiltration,
TNBS-induced [12] Inflammation, loss of goblet cells, vasc
colon
TNBS-induced [13] Crypt distortion, goblet cell loss, ac
TNBS-induced [14] Loss of mucosal architecture, cellular infilt
gobl
Acetic acid-induced [15] Inflammation, bleeding, ulce
TNBS-induced [16] Percentage of area, crypt loss (both
infi
HLA-B27 transgenic mice [17] Inflammation, goblet cell loss, mucosa
(each 0–4), u
IL10-deficient mice [18] Mucosal ulceration, epithelial hyperpla
Lamina propria
IL10-deficient mice [19] Inflammation/epithelial erosion/ulce
(together 0–4) multiplied
MHC missmatch [20] Active inflammation (0.5-3), chronic inflam
af
Amebic colitis [21] Number of amoeba (0–5)
Small intestinal diseases
Clostridial toxicosis [22] Epithelial damage, hyp
Intestinal ischemia [23] Normal mucosa (0), villous edema (1), s
denuded villi (4), loss of villous tiss
tra
Intestinal ischemia [24] Mucosal damage, inflamm
Jejunitis [25] Villous length, villous tips, epithelium
hem
Bacterial ileitis [26] Hemorrhage, villous atrophy/necrosis, ede
Gastric diseases
Helicobacter-induced [27] Five areas mu
DSS, Dextran sodium sulfate; TNBS, 2,4,6-trinitrobenzene sulfonic acid, MHC, Major h
Interleukin 10.at an exclusion of an observer bias [2]. Image analysis
approaches usually use one or only few two dimensional
planar sections of the tissue of interest to measure three-
dimensional objects. This two-dimensional approach thus
may also lead to biased results. Stereology, which is based
on systematic random sampling and estimates third di-
mensional information, has been developed to avoid thisal disease models
m: parameters (scale width) Citations
loss (0–4), inflammation (0–3) both quantified by the
fected area (0–4)
718
, necrosis, regeneration (each 3–0) 321
ration (each 0–4), extent (0–3), inflammation (0–3), 255
, epithelial hyperplasia (0–4), inflammation (0–3) each
rcentage of involved area (0–4)
185
(0–3), ulceration (0,1), area involved (0–4) 147
inflammation, epithelial damage character, extent of
lial damage (each 0–3)
130
ell/crypt loss), infiltration (each 0–4) 103
tissue damage (each 0–3) 89
ular density, transmural infiltration, thickening of the
wall (together 0–4)
788
ute inflammation, chronic inflammation (each 0–2) 126
ration, muscle thickening (each 0–3), crypt abscesses (0,1),
et cell depletion (0,1)
97
r size, deepness, perforation (together 0–6) 132
0–4) number of follicles, edema, erosion/ulceration,
ltration (each 0–3)
57
l thickening, submucosal infiltration, architecture loss
lcer, crypt abscess (each 0,1)
423
sia (both 0–3), Lamina propria mononuclear infiltrate,
neutrophil infiltrate (each 0–2)
423
rs/hyperplasia/crypt abscesses/goblet cell depletion
by no. of affected colon segments (1–5)
555
mation (0.5-3), villous architecture (1–3) multiplied by the
fected area (0.5-4)
83
, ulceration (0-100%), inflammation (0–5) 58
eremia/edema, neutrophils (each 0–3) 202
ubepithelial edema (2), epithelium loss at villi sides (3),
ue (5), crypt infarction (6), transmucosal infarct (7),
nsmural infarct (8)
270
ation, hyperemia/hemorrhage (each 0–5) 72
, inflammation, crypt loss (each 0–2), crypt abscesses,
orrhage (each 0,1)
15
ma, congestion, neutrophils, epithelial necrosis (each 0–3) 1
ltiplied by inflammation (0–3) 49
istocompatibility complex; HLA-B27, Human Leukocyte Antigen-B27, IL10,
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ticated method for the quantification of histologic in-
formation. It is however by comparison a laborious
and complex method which is established in only few
laboratories.
Semiquantitative scoring systems are therefore still the
most widely used methods to include histopathologic in-
formation in biomedical research. These scoring systems
usually include multiple parameters which are separately
quantified on an ordinal scale and finally combined in a
total score. Average scores of the different experimental
groups can then be compared by non-parametric statistical
tests. The selection of the parameters should be based on
the scientific hypothesis or question together with the
current knowledge on the morphologic outcome of the in-
vestigated disease model. It may therefore be useful to de-
sign individual scoring system for each study which in the
best possible way answers the particular scientific question.
Standard scoring systems for specific disease models on
the other hand allow for the comparison of the results of
different studies.
Several standard scoring systems for different mouse
models have been introduced or emerged in the past
20 years. Histopathologists are therefore repeatedly
requested by cooperating scientists to evaluate the
outcome of animal studies using standard scoring systems
or to elaborate project specific scoring systems. The
present review is intended to give a comprehensive
overview on the currently most commonly used multi-
parametric, semiquantitative scoring systems for mouse
model histopathology.Figure 1 Flow chart visualizing the approach to identify 153 original,
data search.Results
Scoring systems for murine intestinal disease models
Eighteen original scoring systems for colitis models
could be identified. Most of these scoring systems were
designed for dextran sodium sulfate (DSS)-induced colitis
models but 2,4,6-trinitrobenzene sulfonic acid (TNBS)-in-
duced colitis and several models of immunopathologic col-
itis were also used to establish scoring systems (Table 1,
Figure 1). Eight scoring systems for DSS-induced colitis
fulfilled all required parameters and were included in this
review. Generally, all of the paper with original DSS colitis
scoring systems had a high citation rate but the scoring
system described by Cooper is one of the earliest system
with the highest citation number up to date and can there-
fore be seen as a prototype for DSS-colitis scoring [4]. It
separates the colon into three segments which are then
scored by the parameters of crypt loss, inflammation and
affected area. Although later studies refined and increased
the number of histopathologic parameters the value of this
initial study is the separation of the colon in three seg-
ments and the sophisticated approach to the establishment
of the scoring system. Remarkably, parameters in this study
were chosen and tested according to their correlation with
the clinical symptoms of the mice. This is contrast to the
vast majority of scoring systems presented in this review,
which only rarely stated the rational for choosing the in-
cluded parameters and did not perform a correlation with
the clinical symptoms.
When comparing all original colitis models it becomes
obvious that a wide variety of appellation for the most
common parameters inflammation, crypt and surfacemultiparametric, semiquantiative scoring systems by Pubmed
Klopfleisch BMC Veterinary Research 2013, 9:123 Page 4 of 15
http://www.biomedcentral.com/1746-6148/9/123epithelial damage were used (Table 1). These differences in
the nomenclature make it however difficult to directly
compare the different scoring systems. Less often used pa-
rameters in the colitis scoring systems were goblet cell loss,
regeneration, muscular and epithelial hyperplasia, edema
and the separation between acute and chronic inflamma-
tion. In some cases these singularities of the respective
scoring system seem to be dependent on the objectives of
the study while in most cases the rationale for selection of
the parameters was not given.
The number of identified scoring systems for small in-
testinal disease was significantly lower than for colitis
models and had on average lesser citations (Table 1).
Two independent scoring systems were identified for
intestinal ischemia which include the comprehensible
parameters of hyperemia and hemorrhage as well as
inflammation and epithelial damage and in the case of the
higher cited publication by Park et al. several other more
sophisticated parameters [23,24]. Only two scoring systemsTable 2 Semiquantitative scoring systems for murine osteoar
Osteoarthritis model Scoring system
Arthritis [28] Cartilage structure (0–6), cells (0–3
Arthritis [30] Cartilage destruction (0–6), opti
Arthritis [31] Synovial lining, resident
Collagen-induced [29] Extent of synovitis, cartila
Collagen-induced [32] Inflammation, cartilage
Collagen-induced [33] Infiltration in the exudate, infiltration
bone
Collagen-induced [34] Joint exudate (0–5




Adjuvant-induced [37] Percentage of affected area, synovial hyp
IL1-induced arthritis [38] Synovial infiltration, proteogly
Instability-induced [39] Matrix structure, matrix stainin
Instability-induced [40] Cartilage destruction
Hereditary arthritis [41] Articular cartilage structu
Bacterial arthritis [42] Infiltration (0–4), pannus formation, c
tail
Cartilage repair [43] Cell morphology (0–4), matrix staini
integration
Cartilage repair [44] Cellular morphology (0,2,4), Safranin-O stain
thickness (0–2), bonding (0–2), hy
adjacen
Cartilage repair [45] Relative defect area (0–4), integra
cellular morphology (0–5), de
percentage of new bo
Cartilage repair [46] Filled depth (0–4), integration (0–2),
cellularity (0–2), tidemark fo
Cartilage repair [47] Defect filling (0–4), osteochondral reconstr
IL1, Interleukin 1.for small intestinal enteritis were detected which both in-
cluded villous morphology, epithelial damage and inflam-
mation as the main features (Table 1). Surprisingly, only
one semiquantitative scoring system for gastritis was iden-
tified. Wang et al. scored the severity of Helicobacter-
induced gastritis in a uniparametric scoring of five gastric
areas. For the sake of completeness this studies was in-
cluded in this review although it did not fulfill the criterion
of multiple parameters [27].
Scoring systems for murine osteoarthritis models
Seventeen original semiquantitative, multiparametric
scoring systems were identified for murine osteoarthritis
models (Table 2). Three of these, designated as osteoarth-
ritis in Table 2, are scoring systems for human idiopathic
arthritis and were transferred to the murine model to
allow for comparisons of the model with the human dis-
ease. Of these the the score developed by Mankin et al.
has by far the highest citation number which is mostthritis models
: parameters (scale width) Citations
), Safranin-O-stain (0–4), tidemark integrity (0–1) 1322
onal subgrading (subdivision in 2 subgrades) 197
cell density, inflammation (each 0–3) 49
ge loss, bone erosions (together 0–3) 713
destruction, bone erosion (each 0–3) 273
of the synovial membrane, cartilage destruction,
erosion (each 0–3)
198
), proteoglycan depletion (0–3) 139
mation, cartilage damage (each 0–5) 95
ltration, pannus formation (each 0–3) 95
erplasia, cartilage destruction, bone erosion (each 0–3) 64
can depletion, cartilage damage (each 0–3) 41
g, cellularity, subchondral bone (each 0–8) 85
(0–4), osteophyte formation (0–3) 85
re (0–8), Toluidine blue-staining (0–6) 52
artilage destruction, extra-articular manifestations,
lesion (each 0,1)
145
ng (0–3), surface regularity (0–3), thickness (0–2),
of donor cartilage (0–2)
819
(0–3), structural regularity (0–3), structural integrity (0–2),
pocellularity (0–3), chondrocyte clustering (0–2),
t degeneration (0–3)
297
tion of repair tissue (0–3), matrix staining (0–4),
fect architecture (0–4), surface architecture,
ne (0–4), tidemark formation (0–4)
222
surface architecture (0–3), cell morphology (0–3),
rmation (0–4), Toloudin blue stain (0–2)
130
uction (0–2), matrix staining (0–4), cell morphology (0–4) 96
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scription of human osteoarthritic lesion [28]. The majority
of mouse specific systems were established in collagen-
induced models while models of instability-induced or bac-
terial arthritis models were only rarely used. Of these, the
scoring system by William et al. had the highest citation
number [29]. Twelve of the thirteen osteoarthritis scoring
systems include an evaluation of cartilage damage, nine in-
cluded an infiltration parameter, seven included changes in
perichondral bone structure and six studies evaluated the
extend of synovial infiltration (Table 2). Other parameters
like tidemark integrity, proteoglycan content of the cartil-
age, pannus formation or synovial hyperplasia were used
only in the minority or single scoring systems. Again, in
most of these descriptions of original scoring systems no
rational for inclusion of the respective parameters is given
but their usefulness can be comprehended by reflecting the
general pathogenesis of osteoarthritis.
Scoring systems for murine renal disease models
Fourteen original multiparametric, semiquantitative scor-
ing systems for murine models of renal diseases fulfilled
the required criteria for inclusion in this review (Table 3).
Scoring systems for murine Lupus erythematous models
were the dominant model in the category of renal disease
models with four appearances. Austin et al. published the
lupus nephritis score with the highest citation number
[48]. It uses a complex scoring system with 10 parametersTable 3 Semiquantitative scoring systems for murine renal di
Renal disease model Scoring sy
Lupus nephritis [48] Activity index (glomerular/tubul
i
Lupus nephritis [49] Mesangial thicke
Lupus nephritis [50] Glomerular cell proliferation, l
Lupus nephritis [51] Glomerular inflammation, pr
Toxic nephropathy [52] Glomerular cellularity, hy
Toxic nephropathy [53] Glomerular injury, tubula
in




Diabetic nephropathy [56] Glomeruloscl





Age-associated changes [59] Mesangial proliferat
HIV-nephropathy [60] Tubuloepithelial degeneration/re
glomerular sclerosis,
Obstructive nephropathy [61] Tubular dilation/
HIV, Human immunodeficiency virus; MRL, Murphy Roths Large.and a scale width of four and five respectively and was thus
more sophisticated than the other scoring systems which
used only four different parameters.
Glomerular cellularity and proliferation were the terms
most commonly used in all renal scoring systems ex-
cept one scoring system for obstructive nephropathy
model [61]. In addition, one half of the systems in-
cluded tubulointerstitial infiltration and fibrosis in the
scoring system.
Scoring systems for murine models of neurologic disease
Twenty-two original scoring systems for murine models
of central nervous system (CNS) disease were identified
(Table 4). Scoring systems for experimental autoimmune
encephalomyelitis (EAE) and stroke clearly dominated
results. Due to the wide variety of diseases covered by
the system the selection of parameters to be analyzed also
had a wide variation and was clearly dependent on the
pathophysiology of the disease. But again, the rationale for
inclusion of parameters was not consistently given.
A striking feature of CNS disease scoring systems was
the relatively low number of ordinal scales for param-
eter´s magnitudes and the common inclusion of multiple
anatomical sites into the scoring system (Table 4). This
discrepancy is not addressed in the respective publica-
tions but may be based on the anatomical diversity of
the CNS. Furthermore, the inclusion of absolute values
like lesions/mm2 occurred significantly more often insease models
stem: parameters (scale width) Citation
ointerstitial abnormalities (6-tier, each 0–4)); chronicity
ndex (4-tier, each 0–3)
358
ning, extent of changes (together 0–4) 44
obulation, hyaline droplets, macrophage infiltration
(together 0–3)
25
oliferation, crescent formation, necrosis (each 0–3) 1
pertrophy, thrombosis, dilation (together 0–5) 4
r cysts/casts, podocyte hyperplasia, interstitial
flammation (each 0–4)
33
centage of glomerular affection (each 0–4) 524
omerular sclerosis (0–4), interstitial volume (%) 152
erosis, interstitial fibrosis (each 0–4) 15
unoglobulin deposition, tubular damage,
erular crescents (each 0–3)
8
necrosis, tubular casts, interstitial infiltrates (each 0–4) 244
ion, sclerosis, hyalinization (together 0–5) 27
generation, tubular casts, dilation, interstitial infiltration,
collapse, podocyte hyperplasia (each 0–3)
47
atrophy, interstitial fibrosis (each 0–3) 4
Table 4 Semiquantitative scoring systems for murine central nervous disease models
Disease model Scoring system: parameters (scale width) Citations
Stroke
Focal ischemia [62] Ischemic neuronal damage (0–3) 2176
Focal Ischemia[63] 18 areas x neuronal injury (0–5) 23
Global ischemia [64] Infarcts in 3 cerebral regions (0–4), hippocampus infarction (0–4) 100
Global ischemia [65] Eight regions x neuronal cell los/gliosis/iron deposition/gliosis (0–3) 95
Peripheral nerve ischemia [66] Edema, fiber regeneration (each 0–4) 21
Multiple sclerosis models
EAE [67] Inflammation, neuronal degeneration (each 0–4) 160
EAE [68] Inflammation (cells/cuff), axonal injury, axonal loss (each 0–4) 81
EAE[69] Lesion severity, myelin loss/tissue injury, acute inflammation, chronic inflammation (each 0–5) 79
Theiler's murine encephalomyelitis virus [70] Neuropil inflammation, demyelination, necrosis, meningeal inflammation (each 0–4) 77
EAE [71] Infiltration, demyelination (together 0,1) in 16 regions 64
EAE [72] Inflammation, necrosis (each 0–3) 53
EAE [73] Inflammation (cuffs/100 m2), demyelination (lesions/mm2) 52
EAE [74] Meningitis (0–2), perivascular cuffing (0–5), demyelination (0–3) 43
EAE [75] Spinal cord demyelination (0–3), inflammatory cells (No./mm2) 22
Spinal cord trauma (SCT)
SCT [76] Gray matter degeneration/infarction (0–4) in 5 μm serial sections 33
SCT [77] 150 μm intervals x Area affected by neuronal degeneration, malacia (0–4) 23
Encephalitis/Meningitis
Streptococcus meningitis [78] Meningeal inflammation (0–3) x four regions 46
Trypanosoma encephalitis [79] Meningitis, perivascular cuffing, neuropil infiltration (each 0–4) 41
Miscellaneous CNS diseases
Oxidative damage [80] 7 areas x necrosis (0–3) 27
Senescence [81] Spongiosis (0–3), lipofuscin positive cells (%) 23
Spinocerebellar ataxia [82] Molecular layer thickness, Purkinje cell loss (each 0–3) 10
EAE, Experimental autoimmune encephalomyelitis, SCT, Spinal cord trauma, CNS, Central nervous system.
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is not comprehensible in each case. Only one scoring sys-
tem occurred for a peripheral nerve system disease which
has been developed to evaluate peripheral nerve ischemia
in a relatively simple two-tier system with a zero to four-
scale [66].
Scoring systems for murine models of pulmonary diseases
Fourteen original semiquantitative, multiparametric scor-
ing systems were identified for pulmonary diseases
(Table 5). Of these pulmonary fibrosis and pulmonary in-
flammation were diseases with the highest number scor-
ing systems and citations. For instance, the scoring
system developed by Ashcroft, which is a relatively sim-
ple multiparametric but single scaled system, is com-
monly used for the evaluation of lung fibrosis [83]. Three
scoring systems were developed for models of general
acute lung inflammation (Table 5). They used the param-
eters of edema and anatomical site specific inflammationas parameters to evaluate the relative amount of inflam-
matory response. Similar parameters in a wide variety of
combinations were used to develop scoring systems for
diverse infectious pneumonia models. This variation is
again in most cases not based on reasonable argument
for the inclusion of a certain parameter in a certain model
and therefore not in all cases clearly associated with the
supposed pathogen-associated pathogenesis of the respect-
ive pneumonia.
Scoring systems for myocardial, vascular and muscular
disease models
Three original scoring systems for the evaluation of viral
myocarditis were identified [96-98]. All of them included
the evaluation of the parameters of myocardial necrosis
and inflammation (Table 6). In addition, two of them
also included calcification as a parameter while fibrosis
and Evans blue-staining as a marker of myofiber damage
were used as a parameter of myocardial disease only once.
Table 5 Semiquantitative scoring systems for murine models of pulmonary diseases
Pulmonary disease models Scoring system: parameters (scale width) Citations
Lung fibrosis [83] Alveolar/bronchial wall thickening, structure distortion, fibrosis (together 0–8) 273
Lung fibrosis [84] Fibroblastic foci, established fibrosis, intraalveolar macrophages (each 0–6) 116
Cystic fibrosis [85] Lymphoid infiltrate (0–5), goblet cell hyperplasia (0–2), mucus retention (0–3),
bronchiolitis (0–5), pneumonia (0–3), edema (0–2)
101
Ventilator-induced lung injury [86] Alveolar congestion, hemorrhage, neutrophils in airspaces/vessel walls, alveolar wall
thickness, hyaline membranes (each 0–4)
78
Pulmonary ischemia [87] Edema, inflammatory cell infiltration, vascular congestion, alveolar hemorrhage (each 0–3) 5
Smoke-induced pneumopathy [88] Alveolar emphysema, atelectasis, infiltration, hemorrhage, alveolar wall thickness,
perivascular/peribronchiolar edema (each 0–3)
4
Lung inflammation [89] Perivascular edema (0–3), perivascular/-bronchiolar inflammation (0–3),
goblet cell metaplasia (0–2)
32
Lung inflammation [90] Alvolear wall inflammation, perivenous regions, periarterial/peribronchial regions,
venous/arterial endothelial lesion (each 0–3)
30
Acute lung inflammation [91] Alveolar necrosis, vascular congestion, infiltration by neutrophils/ macrophages (each 0–4) 6
RSV pneumonia [92] Peribronchiolitis, alveolitis, perivasculitis, hypertrophy of mucus-producing glands,
eosinophilia (each 0–5).
26
Mycoplasma pneumonia [93] Quantity/quality of (peri-)bronchial infiltrates, bronchial luminal exudate, perivascular infiltrate,
parenchymal pneumonia (0–3)
56
Pneumocystis carinii infection [94] Cyst number (0–4), inflammation (0–5) 87
Streptococcus pneumonia [95] Bronchitis, edema, interstitial inflammation, intraalveolar inflammation, pleuritis,
endothelialitis (each 0–4)
0
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portant human vascular diseases were identified: athero-
sclerosis, aneurysms and vasculitis (Table 6) [101-103].
They all cover several aspects of the pathogenesis and
pathophysiology of the diseases but have been generally
rarely cited yet. The aneurysm scoring system grades the
severity of the disease by the extent of medial and adventi-
tial lesion together with the general size of the lesion [102].Table 6 Semiquantitative scoring systems for cardiovascular a
Disease model Scoring s
Myocardial diseases
EMCV-induced myocarditis [96] Myocardial necrosis,
Coxsackievirus-induced myocarditis [97] Myocardial necro
Coxsackievirus-induced myocarditis [98] Necrosis, infla
Dilated cardiomyopathy [99] Myocard
Chronic cardiotoxicity [100] Qualitative/quantitat
Vascular diseases
Aneurysm [101] Extent of medial, adv
Atherosclerosis [102] Medial erosion, foam cells, bur
Vasculitis [103] Infiltration, elastic lamin
Muscle diseases
Ischemic necrosis [104] Infiltration, n
Trypanosoma myositis [105] Number of par
EMCV, Encephalomyocarditis virus.The atherosclerosis scoring systems uses a 5-tier system
with a 0–1 scale width [102], whereas the vasculitis score
uses the parameters infiltration, elastic lamina destruction
and intimal thickening, thus indicating that the system may
only be useful for evaluation of larger vessel types [103].
Two scoring systems for muscular disease models were
identified (Table 6). One recently published scoring system
evaluated the extent of Trypanosoma-induced myositisnd muscle disease models
ystem: parameters (scale width) Citations
infiltration, calcification, fibrosis (together 0–4) 50
sis, infiltration, calcification (together 0–4) 33
mmation, Evans blue-stain (each 0–4) 17
ial necrosis, fibrosis (together 0–4) 20
ive myocardial degeneration score (each 0–4) 72
entitial disruption/size of lesion (together 0–6) 21
ied fibrous caps, chondrocyte-like cells, lateral xanthomas
(each 0,1)
2
a destruction, intimal thickening (together 0–3) 8
ecrosis, hemorrhage (together 0–10) 14
asites, eosinophilic infiltration (each 0–3) 0
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quantify the extent of ischemia-induced muscle necrosis by
the parameters necrosis, infiltration and hemorrhage [105].
Scoring systems for hepatic and pancreatic diseases
Ten original scoring systems for chronic hepatitis have
been developed or used for the quantification chronic
hepatic disease (Table 7). The scoring systems by Ishak
and Knodell are both highly cited scoring systems and
cover almost all possible histomorphologic changes in
chronically inflamed livers [106,107]. The two identified
scoring systems for acute hepatitis quantify lesions by
grading the extent of inflammation and necrosis, similar
to the Ishak system for chronic hepatitis [108,109].
Five scoring systems for the evaluation of acute pan-
creatitis have been identified (Table 7). The first and
most commonly cited scoring system was published by
Schmidt et al. [116]. It uses the five parameters edema,
necrosis, inflammation, hemorrhage and fat necrosis to
score the extent of pancreatic lesions. All four later de-
veloped scoring systems only marginally modified the
parameters by omitting a single parameter or including
vacuolization as an additional marker (Table 7). In
addition, one multiparametric but several uniparametric
(data not shown) scoring systems were identified for the
quantification of insulitis in mice models. The scoringTable 7 Semiquantitative scoring systems for murine hepatic
Disease model Scoring
Hepatic disease
Chronic active hepatitis [107] Periportal bridging (0–10), intr
Chronic hepatitis [106] Periportal/septal inflammation
inflammation (0–
Chronic hepatitis [110] Mitotic activity, portal infla
Hepatic fibrosis [108] Centrolobular vein/perisinuso
septa
Acute hepatitis [111] Steatosis (0
Acute hepatitis [109] Portal
Nutritional hepatopathy [112] Hepatocyte degenerati
Alcohol-induced hepatopathy [113] Steatosis (%), i
Non-alcoholic Steatohepatitis [114] Steatosis (0–3), hepatoc
Hepatic ischemia [115] Loc
Pancreatic disease
Acute pancreatits [116] Edema, necrosis, infl
Acute pancreatitis [117] Edema, necros
Acute pancreatitis [118] Edema, necros
Acute pancreatitis [119] Acinar-cell ghost
Ischemia-induced acute pancreatitis [120] Edema, necrosis, inf
Autoimmune pancreatitis [121] Infiltr
Insulitis [122] Islet infisystem by Papaccio et al. uses islet infiltration, atrophy
and destruction as parameters for the evaluation of Isle
of Langerhans inflammation [122].
Scoring systems for skin and ocular diseases and
miscellaneous disease models
Murine psoriasis models are the only skin disease model
with more than one identified scoring system (Table 8).
Both scoring systems offer a wide variety of parameters
for the evaluation of epidermal and dermal changes
in models of this relevant human disease [123,124]. In
addition, scoring systems for dermal sclerosis, burn scars,
atopic dermatitis and epithelial irritation were identified
(Table 8).
Five original scoring systems for the evaluation of ocu-
lar diseases were identified. Two of these systems use
only one parameter for the evaluation of autoimmune and
endotoxin uveitis. For the sake of completeness these scor-
ing systems are also displayed in Table 8, although they do
not fulfill requirements for inclusion [133,134]. Further-
more, the identified scoring system for diabetic retinopathy
uses two parameters evaluated in absolute numbers of leu-
kocytes per area [130].
Three scoring systems for the evaluation of abdominal
adhesions after traumatic or toxic irritation of the peri-
toneum could be identified. Interestingly, not all scoringand pancreatic disease models
system: parameters (scale width) Citations
alobular necrosis, portal inflammation, fibrosis (each 0–4) 2,609
(0–4), confluent necrosis (0–6), focal necrosis/apoptosis/
6), portal inflammation (0–4), fibrosis (0–6)
2,001
mmation, ductular proliferation, councilman bodies,
fibrosis (each 0–3)
107
idal space fibrosis (each 0–2), portal tract fibrosis (0–3),
number (0–3), septa width (0–5)
135
–4), necrosis, inflammation (each 0–2), 218
/lobular inflammation (each 0–3) 41
on, portal inflammation, portal fibrosis (each 0–3) 25
nflammation/necrosis/fibrosis (each 0–2) 8
ellular ballooning (0–2), lobular inflammation (0–2) 1,149
ation, necrosis (together 0–4) 12
ammation, hemorrhage, fat necrosis (each 0–4) 307
is, inflammation, vacuolization (each 0–4) 144
is, inflammation, hemorrhage (each 0–4) 89
s (%), acinar cells vacuolization/swelling (%) 42
iltration, hemorrhage, vacuolization (each 0–3) 14
ation, necrosis, lipomatosis (0–4) 42
ltration, destruction, atrophy (0–5) 49
Table 8 Semiquantitative scoring systems for murine models of eye, skin and miscellaneous diseases
Disease model Scoring system: parameters (scale width) Citations
Skin diseases
Burn scars [125] Epidermal hyperplasia/hyperkeratosis, hair follicles, apocrine glands, smooth muscles, fibroplasia,
vascular proliferation (each 0,1), collagen orientation (0–3)
26
Systemic sclerosis [126] Dermal inflammation, thickened collagen bundles, dermal thickness (each 0–3) 18
Atopic dermatitis [127] Epidermal hypertrophy, hyperkeratosis, parakeratosis, erosion, inflammation, edema, ulcer (each 0–4) 8
UV radiation-induced skin
damage [128]
Epidermal thickness (0–3), dermal cellularity (0–3), dermal cyst changes (0–5) 7
Epithelial irritation [129] Leukocyte infiltration (0–5), epithelial reaction (0,1) 1
Psoriasis [123] Munro abscesses (1.5), hyperkeratosis (0.5), parakeratosis (1), length of rete ridges (0.5–1.5),
lack of granular layer (1), acanthosis (1), dermis lymphocytic infiltrate (0.5–1.5), papillary
papillae congestion (1), thinning above papillae (0.5)
18
Psoriasis [124] Epidermal thickness, Stratum corneum thinning, extent of Stratum granulosum/parakeratosis/
inflammation, microabscesses (each 0–3)
5
Ocular diseases
Diabetic retinopathy [130] Inflammation (leukocytes/100 μm retina length), leukostasis (leukocytes per vessel lumen) 25
Oxygen induced retinopathy [131] Blood vessel growth, tufts, tortuosity, extraretinal neovascularization, vasoconstriction (each 0–3),
hemorrhage (0,1)
48
Bacterial endophthalmitis [132] Inflammation, retinal architecture (each 0–4), 18
Autoimmune uveoretinitis [133] Infiltration (0–4) 285
Endotoxin uveitis [134] Inflammation (0–3) 47
Miscellaneous diseases
Abdominal adhesion [135] Inflammation, fibrosis, necrosis/abscess, granulomas (each 0–3) 100
Abdominal adhesion [136] Vessel number, neutrophil infiltration, neutrophils at site (each 0–3) 4
Abdominal adhesion [137] Fibrotic matrix, collagen fibers, fibroblast proliferation (together 1–5) n.r.
Embryonic development [138] Grading (0–5) of 17 parameters 429
Wound healing [139] Infiltration, granulation tissue, fibroblasts, collagen deposition (together 0–12) 369
Thyroiditis [140] Number of inflammatory foci, parenchymal destruction (together 0–4) 77
Vaginitis [141] Epithelial disruption, leucocyte infiltration, edema, vascular injection (each 0–4) 74
Esophagitis [142] Epithelial damage/hemorrhage (0–4), inflammation (0–3) 6
Lymph node [143] Heterophils, apoptotic histiocytes, sinus histiocytosis, follicular hyperplasia (together 0–5) 1
Spermatogenic activity [144] Presence of spermatozoa/spermatides/germ cells/sertoli cells (together 0–10) n.r.
n.r., not reported; UV, ultraviolet light.
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eter for the grading of the adhesions [135-137]. Finally,
very helpful scoring systems for the evaluation of embry-
onic development and wound healing could be identified
(Table 8).
Scoring systems for systemic diseases and transplant
rejection
Three original scoring systems analyzing lesions associ-
ated with graft-versus-host disease (GvHD) are avail-
able (Table 9). The most cited scoring system by Hill
et al. exclusively covers intestinal lesions associated with
GvHD [145]. This system allows a very thorough ana-
lysis of intestinal lesion using a wide variety of parame-
ters in the small and large intestine. The other two
systems also cover intestinal lesions but provide additionalparameters for the analysis of hepatic [146] or hepatic and
skin lesions [147].
Three original scoring systems have been developed
for the analysis lesions associated with hemorrhagic
shock (Table 9). The scoring system with the highest cit-
ation number only focusses on the pulmonary lesion and
offers a variety of parameters for the evaluation of
shock-induced lesions in the lung [148]. The other two
scoring system also include parameters for lung evalu-
ation but both offer additional parameters for the quan-
tification of intestinal changes [149,150] or in one case
offer scoring systems for renal and hepatic lesions [150]
associated with hemorrhagic shock.
The identified scoring system for immunotoxicity
of toxins more or less demands the analysis of all
immune organs but gives a good guideline in terms of the
Table 9 Semiquantitative scoring systems for systemic disease models
Disease model Scoring system: parameters (scale width) Citations
Graft-versus-host disease (GvHD)
Intestinal acute GvHD [145] Small intestine: villous blunting, crypt regeneration/apoptosis/loss, enterocyte loss,
infiltration (each 0–4); Colon: crypt regeneration, colonocyte vacuolization, crypt
apoptosis/destruction, infiltration (each 0–4)
389
Acute GvHD [146] Small/large bowel: villous blunting, crypt regeneration/apoptosis/loss, luminal sloughing, infiltration,
mucosal ulceration, epithelial/vacuolization (each 0–4), liver: portal infiltration, bile duct apoptosis/
sloughing, parenchymal apoptosis/abscesses/mitoses, steatosis, cholestasis (each 0–4)
170
Acute GvHD [147] Skin: epidermal damage, dermal collagen density, dermal infiltration, subcutaneous fat loss,




Lung lesion [148] Alveolar membrane thickening, congestion, edema, intraalveolar hemorrhage, interstitial,
intraalveolar infiltration (each 0–3)
36
Intestinal, pulmonary lesions [149] Intestine: % injury (number of edematous villi x 0,5 + number of villi with epithelial damage x 1),




Lung: atelectasis, hemorrhage, edema, congestion, inflammation, hyp-eraeration (each 0–3); ileal
mucosal damage, (0–5), liver: congestion, necrosis, vacuolization (each 0–3), Kidney: epithelial
swelling, tubular dilation, necrosis, edema, microthrombosis (each 0–3)
2
Immunotoxicity
[151] Complete assessment of all lymphoid organs (each 0–4) 50
Transplant rejection
Banff classification for renal
rejection [152]
Tubulitis, arteritis, mononuclear cell interstitial infiltrates, glomerulitis, interstitial fibrosis,
tubular atrophy, glomerulopathy, mesangial matrix increase, vascular fibrous intimal
thickening, arteriolar hyaline thickening (each 0–3)
1.727
Heart rejection 1990 [153] Infiltration, myocyte damage (0–4) 1401
Heart rejection 2005 [154] Infiltration, myocyte damage (0–3) 365
Lung rejection [155] Inflammation (0–4), lymphocyte infiltration (0–1), bronchiolitis obliterans (0–4), Vascular
rejection (0–1), vasculitis (0–1)
362
Skin rejection [156] Acanthosis, ulceration, necrosis, inflammation, granulation tissue (0–5) 1
GvHD, Graft versus host disease.
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toxin application (Table 9) [151].
Finally, the three scoring systems which have been used
for murine transplant rejection models have consistently
been developed for the evaluation of tissues from human
patients (Table 9). They are all used in mouse models un-
modified to allow for better conclusions from the mouse
models for the situation in the human patient.
Discussion
Extensive research of the literature identified 146 origin-
ally designed semiquantitative, multiparametric scoring
systems for the histopathology of mouse models. These
scoring systems cover almost all organs systems and a
wide variety of disease models. Colitis and especially ul-
cerative colitis was the disease model with the largest
number of different scoring system closely followed by
experimental autoimmune encephalitis (EAE), lupus neph-
ritis and collagen induced osteoarthritis.
The number of citations for the publication including
the scoring system varied between few citations and upto 2176. The citation number clearly reflects the value
of the scientific work shown in the papers and thus also
indirectly reflects the quality of the included scoring
systems. In some cases there is even clear evidence that
the high citation number is directly based on the “gold”
standard character of the scoring system and its regular
use in mouse models or human tissues, for instance the
score from Mankin et al. for osteoarthritis evaluation
and the scores developed by Knodell and Ishak et al.
for chronic hepatitis or the score by Cooper et al. for
DSS-colitis [4,28,106,107]. Nevertheless, after careful
analysis of the publication it also became obvious that
scoring systems in publications with a small number of
citation also proofed to be of expedience for certain sci-
entific question.
Assuming that the main function of scoring systems is
the analysis of the influences of experimental factors on
the microscopical tissue morphology the selected param-
eters should be consciously chosen to be able to reflect
the potential changes. The lack of a rationale for the se-
lection of the parameters was therefore an emerging and
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study. Although the selection of parameters in most
scoring systems is comprehensibly based on the com-
mon knowledge on the pathogenesis of the disease mod-
eled in the mouse, there is only rarely a clear statement
or a line of argument for choosing a parameter. Even
less often the correlation between scoring parameter
value and the magnitude of the clinical symptoms or the
differences in the extent of the experimental factor is
given as for instance in the excellent study of Cooper
et al. [4]. This lack is most probably due to the time-
consuming work involved, but it may however tremen-
dously increase the value and the scientific merit of the
scoring system.
Conclusion
In summary, a final judgment of the quality and the use-
fulness of the scoring systems presented was not an aim
of this study and is after all most probably not possible
since the value of a scoring system clearly depends on
the scientific question, the underlying hypothesis, the
model characteristics and the pathogenesis of the dis-
ease. This review may however give an overview on cur-
rently available scoring systems and may therefore allow
for a better choice for the respective project.
Methods
Selection of scoring systems
The systematic review was prepared according to the
PRISMA guidelines [157]. All items were considered and
can be viewed in Additional file 1. Scoring systems were
identified by a comprehensive Pubmed search (http://
www.ncbi.nlm.nih.gov/pubmed/) using a combination of
the search terms “mouse”, “score”, “histopathology”. This
led to the identification of 1479 publication by October
30, 2012 (Figure 1). Full text versions of all publications
were obtained and analyzed for the description of multi-
parametric, semiquantitative, scoring systems for the
histopathology of mouse models. Inclusion of a mouse
scoring system in this overview was based on the fulfill-
ment of six parameters.
First, the scoring system had to be based on the semi-
quantitative evaluation of histopathologic changes in mur-
ine tissues. Thus, approaches using digital image analysis
for absolute quantification of lesion area, cell number or
immunohistochemical signals or scoring systems with
dominance of immunohistochemical markers as evaluation
parameters were not included.
Second, only scoring systems evaluating more than
one histomorphologic parameter were included in the
review. Nevertheless, scoring systems with high citation
numbers which combined several parameters in a uni-
parametric score were also included. For instance, if a
highly cited scoring system integrated the presence andextent of crypt abscesses, epithelial sloughing and sub-
mucosal infiltration into a single score of 0 to 4 the study
was also included.
Third, the scoring approach had to be comprehensibly
described to allow for reproduction by the reader.
Fourth, the scoring system had to be originally designed
for the presented study without citation of former publica-
tions. If former publications were cited as the source of the
scoring system, the string of citations was followed back to
the study originally describing the scoring systems. If scor-
ings systems were not referenced to older studies but simi-
lar approaches were detected in earlier publication, only
the older study was included in this review.
Fifth, the scoring systems were generally grouped by the
organ affected and analyzed. Systemic diseases and trans-
plantation models were included in separate groups. If the
number of identified scoring systems for a specific disease
model exceeded ten, only the then most cited scoring sys-
tems were included in this review.
Citation number was obtained using Thomson Reuters
Web Science© (http://apps.webofknowledge.com).
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